A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies. Background: LYC-55716 is a first-in-class, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback